OliX Pharmaceuticals,Inc (226950.KQ)
KRW 18430.0
(-6.07%)
KRW 18430.0
(-6.07%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 27.37 Billion KRW | -29.93% |
| 2022 | 39.06 Billion KRW | 1231.45% |
| 2021 | 2.93 Billion KRW | -8.25% |
| 2020 | 3.19 Billion KRW | 167.58% |
| 2019 | -4.73 Billion KRW | -68.23% |
| 2018 | -2.81 Billion KRW | -489.6% |
| 2017 | 721.95 Million KRW | -35.02% |
| 2016 | 1.11 Billion KRW | 158.55% |
| 2015 | -1.89 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 15.17 Billion KRW | -44.58% |
| 2024 Q2 | 41.65 Billion KRW | 174.56% |
| 2023 Q1 | 36.59 Billion KRW | -6.33% |
| 2023 FY | 27.37 Billion KRW | -29.93% |
| 2023 Q3 | 37.29 Billion KRW | -3.84% |
| 2023 Q2 | 38.77 Billion KRW | 5.97% |
| 2023 Q4 | 27.37 Billion KRW | -26.59% |
| 2022 Q2 | -25.58 Billion KRW | -229.29% |
| 2022 FY | 39.06 Billion KRW | 1231.45% |
| 2022 Q4 | 39.06 Billion KRW | 55.23% |
| 2022 Q3 | 25.16 Billion KRW | 198.34% |
| 2022 Q1 | 19.79 Billion KRW | 574.55% |
| 2021 Q4 | 2.93 Billion KRW | 91.83% |
| 2021 Q1 | 8.06 Billion KRW | 174.25% |
| 2021 Q2 | -879.9 Million KRW | -110.92% |
| 2021 Q3 | 1.52 Billion KRW | 273.82% |
| 2021 FY | 2.93 Billion KRW | -8.25% |
| 2020 Q4 | 2.93 Billion KRW | 313.6% |
| 2020 FY | 3.19 Billion KRW | 167.58% |
| 2020 Q1 | -6.19 Billion KRW | -30.52% |
| 2020 Q2 | -1.38 Billion KRW | 77.71% |
| 2020 Q3 | -1.37 Billion KRW | 0.36% |
| 2019 Q4 | -4.74 Billion KRW | 56.53% |
| 2019 FY | -4.73 Billion KRW | -68.23% |
| 2019 Q3 | -10.92 Billion KRW | -269.38% |
| 2019 Q2 | -2.95 Billion KRW | 44.27% |
| 2019 Q1 | -5.3 Billion KRW | -88.65% |
| 2018 Q1 | 14.85 Billion KRW | 0.0% |
| 2018 Q4 | -2.81 Billion KRW | 0.0% |
| 2018 FY | -2.81 Billion KRW | -489.6% |
| 2017 FY | 721.95 Million KRW | -35.02% |
| 2016 FY | 1.11 Billion KRW | 158.55% |
| 2015 FY | -1.89 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 159.274% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 167.451% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 39.633% |
| Bioneer Corporation | -3.9 Billion KRW | 800.519% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -227.772% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -84.786% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -204.438% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 212.073% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 92.962% |
| Medy-Tox Inc. | 49.58 Billion KRW | 44.791% |
| Peptron, Inc. | 4.86 Billion KRW | -462.269% |
| Amicogen, Inc. | 125.26 Billion KRW | 78.146% |
| Genexine, Inc. | 61.39 Billion KRW | 55.412% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 300.009% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 148.837% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 48.899% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 183.109% |
| SillaJen, Inc. | -13.89 Billion KRW | 297.06% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 67.519% |
| Genomictree Inc. | -43.43 Billion KRW | 163.025% |
| MedPacto, Inc. | -64 Billion KRW | 142.773% |
| D&D Pharmatech | -7.5 Billion KRW | 464.618% |
| EASY BIO,Inc. | 53.21 Billion KRW | 48.554% |
| GI Innovation, Inc. | -4.82 Billion KRW | 667.646% |